Ablynx: PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR

Ablynx: PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY
2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

REGULATED INFORMATION

GHENT, Belgium, 8 July 2014 -Ablynx [Euronext Brussels: ABLX] today announced,
in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the
publication of major shareholdings in issuers whose securities are admitted to
trading on a regulated market (the "Transparency Law"), that it received a
notification of shareholdings from FMR LLC.

The above legal entity informed that  it has been granted discretionary  power 
to vote for more than 3% of Ablynx' voting rights, as it shall exercise voting
rights incorporated in 1,810,500 Ablynx  shares, which represent 3.35% of  the 
current 53,991,659 outstanding shares of Ablynx.

Such voting rights shall be exercised by FMR LLC, which controls the following
companies acting  as  fund manager  for  various undertakings  for  collective 
investment, that hold a participation in Ablynx shares: Fidelity Management  & 
Research Company,  Pyramis Global  Advisors LLC  and Pyramis  Global  Advisors 
Trust Company.

Full versions of all transparency  notifications are available on the  website 
of Ablynx, under the section Investors.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development
of NanobodiesĀ®, a novel class  of therapeutic proteins based on  single-domain 
antibody  fragments,  for  a  range  of  serious  human  diseases,   including 
inflammation, haematology, oncology and pulmonary disease. Today, the  Company 
has more than 30 programmes in  the pipeline and seven Nanobodies in  clinical 
development. Ablynx  has  on-going  research  collaborations  and  significant 
partnerships with major pharmaceutical companies including AbbVie,  Boehringer 
Ingelheim, Merck & Co, Merck Serono and Novartis. The Company is headquartered
in Ghent, Belgium. More information can be found on www.ablynx.com.

Voor bijkomende informatie, gelieve contact op te nemen met

Ablynx:

Dr Edwin Moses
Gedelegeerd Bestuurder
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
 +32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com
Volg ons op Twitter @AblynxABLX

Ablynx media relaties Consilium Strategic Communications:

Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
t: +44 203 709 5700
e: ablynx@consilium-comms.com

pdf format of the press release

------------------------------------------------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf
of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for
the content, accuracy and originality of the information contained therein.
Source: Ablynx via Globenewswire
HUG#1818479
 
Press spacebar to pause and continue. Press esc to stop.